0000899243-20-020587.txt : 20200729
0000899243-20-020587.hdr.sgml : 20200729
20200729060637
ACCESSION NUMBER: 0000899243-20-020587
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200729
DATE AS OF CHANGE: 20200729
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 201055622
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-28
1
0001693011
Inozyme Pharma, Inc.
INZY
0001121404
Sanofi
54 RUE DE LA BOETIE
PARIS
I0
75008
FRANCE
0
0
1
0
Common Stock (par value $0.0001)
2020-07-28
4
C
0
438875
0.00
A
438875
I
Through its wholly-owned subsidiary, Aventis Inc.
Common Stock (par value $0.0001)
2020-07-28
4
P
0
81250
16.00
A
520125
I
Through its wholly-owned subsidiary, Aventis Inc.
Series A Convertible Preferred Stock (par value, $0.0001)
0.00
2020-07-28
4
C
0
3279720
0.00
D
Common Stock
438875
0
I
Through its wholly-owned subsidiary, Aventis Inc.
On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY.
The reporting person acquired additional shares in the Issuer's initial public offering.
/s/ Alexandra Roger, Head of Securities Law and Capital Markets
2020-07-29